Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more
Dr. Reddy's Laboratories Limited (RDDA) - Net Assets
Latest net assets as of September 2025: €362.08 Billion EUR
Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has net assets worth €362.08 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€542.00 Billion) and total liabilities (€179.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €362.08 Billion |
| % of Total Assets | 66.8% |
| Annual Growth Rate | 13.31% |
| 5-Year Change | 92.69% |
| 10-Year Change | N/A |
| Growth Volatility | 6.52 |
Dr. Reddy's Laboratories Limited - Net Assets Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual net assets of Dr. Reddy's Laboratories Limited from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €337.17 Billion | +20.18% |
| 2024-03-31 | €280.55 Billion | +20.48% |
| 2023-03-31 | €232.86 Billion | +22.22% |
| 2022-03-31 | €190.53 Billion | +8.88% |
| 2021-03-31 | €174.98 Billion | +12.90% |
| 2020-03-31 | €154.99 Billion | +10.55% |
| 2019-03-31 | €140.20 Billion | +10.86% |
| 2018-03-31 | €126.46 Billion | +1.95% |
| 2017-03-31 | €124.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dr. Reddy's Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 192.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €315.79 Billion | 94.72% |
| Other Components | €17.59 Billion | 5.28% |
| Total Equity | €333.39 Billion | 100.00% |
Dr. Reddy's Laboratories Limited Competitors by Market Cap
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daqin Railway Co Ltd
SHG:601006
|
$7.30 Billion |
|
Element Solutions Inc
NYSE:ESI
|
$7.30 Billion |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
$7.31 Billion |
|
OBIC Co.Ltd
F:OBL
|
$7.31 Billion |
|
Semtech Corporation
NASDAQ:SMTC
|
$7.28 Billion |
|
Bankinter S.A
PINK:BKIMF
|
$7.28 Billion |
|
STORA ENSO OYJ A EO 170
F:ENUA
|
$7.28 Billion |
|
EPAM Systems Inc
NYSE:EPAM
|
$7.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dr. Reddy's Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 280,550,000,000 to 333,388,000,000, a change of 52,838,000,000 (18.8%).
- Net income of 56,544,000,000 contributed positively to equity growth.
- Dividend payments of 6,662,000,000 reduced retained earnings.
- Share repurchases of 1,389,000,000 reduced equity.
- New share issuances of 193,000,000 increased equity.
- Other factors increased equity by 4,152,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €56.54 Billion | +16.96% |
| Dividends Paid | €6.66 Billion | -2.0% |
| Share Repurchases | €1.39 Billion | -0.42% |
| Share Issuances | €193.00 Million | +0.06% |
| Other Changes | €4.15 Billion | +1.25% |
| Total Change | €- | 18.83% |
Book Value vs Market Value Analysis
This analysis compares Dr. Reddy's Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €748.42 | €12.00 | x |
| 2018-03-31 | €762.22 | €12.00 | x |
| 2019-03-31 | €845.33 | €12.00 | x |
| 2020-03-31 | €934.92 | €12.00 | x |
| 2021-03-31 | €1055.84 | €12.00 | x |
| 2022-03-31 | €1148.07 | €12.00 | x |
| 2023-03-31 | €1401.45 | €12.00 | x |
| 2024-03-31 | €336.94 | €12.00 | x |
| 2025-03-31 | €400.71 | €12.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dr. Reddy's Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.96%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.37%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.48x
- Recent ROE (16.96%) is above the historical average (13.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 9.71% | 8.55% | 0.64x | 1.77x | €-365.40 Million |
| 2018 | 7.75% | 6.90% | 0.63x | 1.78x | €-2.84 Billion |
| 2019 | 13.41% | 12.22% | 0.68x | 1.61x | €4.78 Billion |
| 2020 | 12.58% | 11.17% | 0.75x | 1.50x | €4.00 Billion |
| 2021 | 10.94% | 10.09% | 0.71x | 1.52x | €1.65 Billion |
| 2022 | 12.37% | 10.99% | 0.72x | 1.56x | €4.52 Billion |
| 2023 | 19.36% | 18.33% | 0.76x | 1.39x | €21.79 Billion |
| 2024 | 19.85% | 19.95% | 0.72x | 1.38x | €27.63 Billion |
| 2025 | 16.96% | 17.37% | 0.66x | 1.48x | €23.21 Billion |
Industry Comparison
This section compares Dr. Reddy's Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dr. Reddy's Laboratories Limited (RDDA) | €362.08 Billion | 9.71% | 0.50x | $7.29 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |